Pharmacological correction of etoposide ovariotoxicity.
The possibility of reducing the ovariotoxicity of antitumor drug etoposide with buserelin, a hypothalamic regulator of pituitary function, was studied in female Wistar rats. Quantitative analysis of ovarian structural and functional elements on serial sections through the entire organ showed that 3 months after combined treatment with etoposide and buserelin, the morphological picture of the ovarian glands did not differ from that in intact animals of the same age, while etoposide monotherapy led to earlier development of atrophic processes. Six months after treatment, the number of bi- and multilayer follicles was significantly higher in rats receiving combined therapy compared to animals treated with etoposide alone.
Borovskaya
T G
TG
Institute of Pharmacology, Tomsk Research Center, Siberian Division of Russian Academy of Medical Sciences, Russia.
Timina
E A
EA
Perova
A V
AV
Pakhomova
A V
AV
Shchemerova
Yu A
YA
Gol'dberg
V E
VE
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000633:toxicity*; D002064:Buserelin / Q000494:pharmacology*; D005047:Etoposide / Q000633:toxicity*; D005260:Female; D005300:Fertility Agents, Female / Q000494:pharmacology*; D010053:Ovary / Q000187:drug effects*; D051381:Rats; D017208:Rats, Wistar
D000972:Antineoplastic Agents, Phytogenic; D005300:Fertility Agents, Female; D005047:Etoposide; D002064:Buserelin